ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 2, 2009, Pages 173-178

  Banfor, Patricia N ^a   Franklin, Pamela A ^a   Segreti, Jason A ^a   Widomski, Deborah L ^a   Davidsen, Steven K ^a   Albert, Daniel H ^a   Cox, Bryan F ^a   Fryer, Ryan M ^a   Gintant, Gary A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 869; Antiangiogenesis; Atrasentan; Platelet derived growth factor; Receptor tyrosine kinase; Vascular endothelial growth factor

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; ATRASENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; N (4 (3 AMINO 1H INDAZOL 4 YL)PHENYL) N1 (2 FLUORO 5 METHYLPHENYL)UREA; N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N1-(2-FLUORO-5-METHYLPHENYL)UREA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HEART RATE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TELEMETRY; TUMOR GROWTH; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; AREA UNDER CURVE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEART RATE; HYPERTENSION; INDAZOLES; MALE; PHENYLUREA COMPOUNDS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ENDOTHELIN A; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TELEMETRY;

EID: 65549092226     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181993493     Document Type: Article

References (20)

1. Dai Y, Hartandi K, Ji Z, et al. Discovery of N-(4-(3-amino-1H-indazol-4- yl) phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazolebased orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem. 2007;50:1584-1597. (Pubitemid 46564379)
2. Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 2001;7:1073-1078. (Pubitemid 32708747)
3. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045-3054. (Pubitemid 47218051)
4. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65: 4389-4400. (Pubitemid 40775678)
5. Yu JC, Li W, Wang LM, et al. Differential requirement of a motif within the carboxyl-terminal domain of alpha-platelet-derived growth factor (alpha PDGF) receptor for PDGF focus forming activity chemotaxis, or growth. J Biol Chem. 1995;270:7033-7036.
6. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50: 203-218. (Pubitemid 47095077)
7. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother. 2006;40: 2278-2279. (Pubitemid 44954457)
8. van Heeckeren WJ, Ortiz J, Cooney MM, et al. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol. 2007;25: 2993-2995. (Pubitemid 47218042)
9. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006; 5:995-1006. (Pubitemid 43724600)
10. Goh BC, Thng CH, Sukri N, et al. Phase 1 study of AVT869, a multiple receptor tyrosine kinase inhibitor, in patents with refractory solid malignancies. Eur J Cancer Suppl. 2006;4:108.
11. Blasi E, Steidl J, Patyna S, et al. Modification of sunitinib malate (SU1248) blood pressure changes in rats. Paper Presented at: Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA.
12. Curwen JO, Musgrove HL, Kendrew J, et al. Inhibition of vascular endothelial growth factor-A signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res. 2008;14:3124-3131.
13. Fryer RM, Rakestraw PA, Banfor PN, et al. Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade. Am J Physiol Heart Circ Physiol. 2006;290:H2554-H2559.
14. Winn M, von Geldern TW, Opgenorth TJ, et al. 2,4-Diarylpyrrolidine- 3-carboxylic acids-potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem. 1996;39:1039-1048. (Pubitemid 26082937)
15. Reinhart GA, Preusser LC, Opgenorth TJ, et al. Endothelin and ET(A) receptors in long-term arterial pressure homeostasis in conscious nonhuman primates. Am J Physiol Regul Integr Comp Physiol. 2000; 279:R1701-R1706.
16. Santos SC, Miguel C, Domingues I, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313:1561-1574. (Pubitemid 46589434)
17. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormonerefractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679-689. (Pubitemid 46621903)
18. Chiappori AA, Haura E, Rodriguez FA, et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008;14:1464-1469.
19. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003;97:779-784. (Pubitemid 36131076)
20. Bagnato A, Cirilli A, Salani D, et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res. 2002;62:6381-6384. (Pubitemid 35364090)